Geroprotective Compounds for Longevity: Cyrene, Rapamycin, NAD+

SNIPPET: Geroprotective compounds — molecules that target aging biology directly — are showing cross-species lifespan extension of 21–51% in preclinical models and measurable healthspan improvements in early human trials. Cyrene, trametinib-rapamycin combinations, 3-hydroxybutyrate, and NAD+ boosters represent the most promising candidates, each targeting distinct nodes of the aging network including mTORC1 suppression, MEK-ERK inhibition, cellular senescence delay, and NAD+ synthesis restoration.

THE PROTOHUMAN PERSPECTIVE#

The longevity field has been stuck in a frustrating loop for years: impressive animal data, mediocre human translation, and a supplement industry that outruns the science by a decade. That loop is starting to crack.

What's changed isn't any single molecule — it's the convergence. We now have researchers combining FDA-approved drugs like trametinib and rapamycin for additive lifespan effects in mammals. We have a cellulose-derived solvent (Cyrene) nobody expected to be geroprotective showing neuroprotection across two species. We have the ketone body 3-hydroxybutyrate extending median mouse lifespan by 21%. And we have — finally — human RCT data on NAD+ boosting that moves beyond blood levels to actual quality-of-life endpoints.

This matters because we're no longer asking "can we slow aging?" — we're asking "which combination, at what dose, for which person?" That's a fundamentally different question, and it's one the biohacking community needs to engage with seriously, not with hype cycles.

THE SCIENCE#

Cyrene: The Accidental Geroprotector#

Let me start with the strangest entry on this list. Cyrene (dihydrolevoglucosenone) is a polar, water-miscible solvent derived from cellulose. It was developed as a green chemistry alternative to toxic solvents like N-methyl-2-pyrrolidone. Nobody was looking for an anti-aging compound. That's exactly what makes AlOkda et al.'s findings in npj Aging so interesting^[1].

Cyrene extended lifespan in C. elegans and improved locomotor function, resistance to oxidative stress, thermal stress, osmotic stress, genotoxic stress, and proteotoxic stress. That's not one stress pathway — that's essentially every major stress modality the organism faces. The compound also conferred protection in neurodegenerative models of Alzheimer's, Parkinson's, and Huntington's disease within the same worm model.

The cross-species validation is what elevates this beyond a curiosity. Cyrene also extended lifespan and enhanced oxidative stress resistance in Drosophila melanogaster. Two species, consistent direction, multiple endpoints. The researchers noted that Cyrene's benefits required administration before day 8 in C. elegans to extend longevity — suggesting it acts on early developmental or epigenetic windows rather than simply suppressing late-life damage.

I'm less convinced by the mechanism story so far. The paper identifies involvement in conserved longevity pathways, but the molecular target isn't pinned down yet. That's not unusual for geroprotective discovery — rapamycin was used for years before its full mTORC1 mechanism was elucidated — but it does mean we're far from human translation.

Trametinib + Rapamycin: The Additive Combination#

This one has teeth. Gkioni, Partridge, and colleagues published in Nature Aging — top-tier journal, rigorous methodology — showing that trametinib (an FDA-approved MEK inhibitor used in melanoma treatment) and rapamycin produce additive lifespan extension in mice when combined^[3].

Here's the architecture of why this works. The insulin–IGF–mTORC1–Ras nutrient-sensing network is the most conserved pro-aging pathway across species. Rapamycin blocks mTORC1 signaling. Trametinib inhibits the Ras–MEK–ERK pathway. These are parallel branches of the same network, which is why they don't compete — they stack.

Trametinib alone extended lifespan in both male and female mice (P = 0.0001). The combination with rapamycin was additive with no indication of positive or negative interaction in either sex. The combination also reduced liver tumors in both sexes and spleen tumors in males, while blocking circulating pro-inflammatory cytokines. The inflammatory cytokine suppression is particularly relevant because chronic low-grade inflammation (inflammaging) is a mechanistic driver of virtually every age-related disease.

The catch, though. Trametinib is an oncology drug with real side effects: skin toxicity, diarrhea, cardiac effects. The doses used in these mouse studies may not map cleanly to tolerable human dosing for a chronic geroprotective protocol. And rapamycin's immunosuppressive profile at standard dosing remains a legitimate concern, despite the growing community of physicians prescribing it off-label at low, intermittent doses. Anyone telling you this combination is ready for human anti-aging use tomorrow either hasn't read the pharmacology or is selling you a consultation.

3-Hydroxybutyrate (3HB): The Ketone Body That Delays Senescence#

3-Hydroxybutyrate is the primary ketone body produced during fasting, ketogenic dieting, or exogenous ketone supplementation. An et al. demonstrated in Nutrients that 3HB supplementation extended yeast lifespan by 51.3% and median lifespan of naturally aging mice by 21.0%^[4].

The mechanistic story is compelling. 3HB's anti-aging properties appear mediated through cellular senescence delay and metabolic reprogramming. The compound prolonged healthy lifespan in mice while mitigating age-related tissue morphology changes and organ senescence — meaning not just longer life, but better tissue architecture during that extended period. RNA sequencing and metabolomics data suggest 3HB rewires metabolic pathways in a way that parallels caloric restriction without the caloric restriction.

A 21% median lifespan extension in naturally aging mice is a serious number. For context, rapamycin — the gold standard geroprotector — typically achieves 10–25% depending on the study, sex, and dosing protocol. That puts 3HB in the same conversation, with the significant advantage of being an endogenous metabolite with established safety in humans via ketogenic diets and exogenous ketone supplements.

But here's where it gets complicated. The optimal dose for geroprotective effects in humans is not established. Ketone levels achieved through diet or supplementation vary enormously between individuals, and we don't know the threshold concentration needed for senescence delay in human tissues. The mouse data is encouraging, genuinely. I'd still want replicated mammalian studies before building a protocol around it.

NAD+ Boosting: Human Data That Actually Moves the Needle#

The Qualia NAD+ trial (Blomquist et al.) is a preprint on medRxiv, so I need to be transparent about that — it has not completed peer review^[5]. That said, the study design is solid: randomized, double-blind, placebo-controlled, 63 healthy adults aged 35–76.

Qualia NAD+ increased blood NAD+ levels by an average of 67% compared to 4% with placebo (p < 0.001). More importantly — and this is where most NAD+ studies fail — they measured quality-of-life endpoints. Emotional well-being improved at days 14, 21, and 28. Vitality scores improved at days 21 and 28. Aging-related symptoms improved in females across overall and somatic categories by day 28.

The sex-specific finding is notable: no significant symptom improvements were observed in males. Whether this reflects hormonal interactions with NAD+ metabolism, sample size limitations, or genuine biological divergence is unclear.

The formulation includes niacinamide (234 mg as part of 254 mg vitamin B3), plus Coffeeberry whole coffee fruit extract. This is an industry-funded study from Qualia Life Sciences, so I apply my standard conflict-of-interest discount. The NAD+ increase is real and robust. The subjective improvements are real but modest. I'm not yet convinced this translates to measurable changes in biological aging markers — they didn't measure epigenetic clocks, telomere dynamics, or any molecular aging biomarker.

Fasting Mimetics: Mimio's Cardiometabolic Play#

Grant, Rhodes, and colleagues tested Mimio — a formulation containing spermidine, nicotinamide, palmitoylethanolamide (PEA), and oleoylethanolamide (OEA) — in overweight adults with elevated HbA1c^[6]. Another medRxiv preprint, another industry-funded study. But the results are interesting.

Mimio improved hunger and satiety composite scores, reduced oxidative stress markers, improved digestive symptoms, and shifted cardiometabolic markers in a favorable direction — all without requiring participants to actually fast. This is the first study to suggest that fasting mimetic supplementation can recreate clinical fasting-like cardiometabolic benefits without lifestyle changes.

The autophagy pathway stimulation from spermidine and the NAD+ precursor activity of nicotinamide make mechanistic sense. PEA and OEA act on endocannabinoid-adjacent pathways that regulate satiety and inflammation. The combination targets multiple upstream aging pathways simultaneously.

COMPARISON TABLE#

THE PROTOCOL#

Based on currently available evidence — and I want to emphasize that most of this is preclinical or early-stage human data — here's a tiered approach for those who choose to engage with geroprotective strategies.

Step 1: Establish your baseline. Before adding any geroprotective compound, measure your biological age using an epigenetic clock test (TruAge, GrimAge, or equivalent). Record fasting glucose, HbA1c, hs-CRP, lipid panel, and NAD+ levels if accessible. This gives you a pre-intervention reference point — without it, you're flying blind.

Step 2: Start with endogenous pathway activation. Before reaching for supplements, optimize the pathways your body already has. Implement time-restricted eating (16:8 minimum) to activate autophagy pathways naturally. This costs nothing and has the strongest human evidence base. Add 2–3 sessions per week of zone 2 cardio to improve mitochondrial efficiency and NAD+ recycling through the electron transport chain.

Step 3: Consider NAD+ precursor supplementation. Based on the Blomquist et al. data, a combination of niacinamide (200–250 mg), vitamin B1 and B2 cofactors, and whole coffee fruit extract may boost NAD+ levels meaningfully over 28 days. Monitor subjective energy and well-being weekly. The evidence suggests females may see greater symptom improvement than males.

Step 4: Introduce ketone exposure. Based on the 3HB data from An et al., periodic elevation of blood ketone levels may support senescence delay. Options include: a 2–3 day monthly fast, cyclic ketogenic dieting (5 days per month), or exogenous ketone supplementation (beta-hydroxybutyrate salts or esters, 5–10g daily during targeted periods). The optimal chronic dose for human geroprotection is not yet established — I want to be honest about that.

Step 5: Explore fasting mimetics cautiously. If consistent fasting is impractical, a fasting mimetic containing spermidine (1–5 mg), nicotinamide, PEA, and OEA taken with the first meal may offer partial autophagy pathway activation. This is early data. Treat it as an experiment, not a prescription.

Step 6: Pharmaceutical geroprotectors — physician supervision only. Rapamycin (1–5 mg weekly, intermittent dosing) under physician guidance has the most extensive geroprotective data in mammals. The trametinib combination is strictly research-stage. Do not self-administer oncology drugs based on mouse data. I shouldn't have to say that, but I do.

Step 7: Retest at 90 days. Repeat your baseline panel at 90 days. Compare biological age estimates, inflammatory markers (hs-CRP), and metabolic markers. Adjust protocol based on data, not feelings.

What is a geroprotective compound and how does it differ from a standard supplement?#

A geroprotector is any compound that targets the biological mechanisms of aging itself — not a single disease, but the upstream processes (mTORC1 signaling, cellular senescence, NAD+ decline, inflammatory cascades) that drive multiple age-related diseases simultaneously. Standard supplements typically address nutrient deficiencies. Geroprotectors aim to modify the rate of biological aging at the molecular level, which is a fundamentally different therapeutic goal.

How much does NAD+ decline with age, and can supplementation fully restore it?#

NAD+ levels decline progressively from around age 30, with some studies estimating a 50% reduction by age 60 in certain tissues. Supplementation with precursors like niacinamide can increase blood NAD+ levels by approximately 67% over 28 days based on the Blomquist et al. trial, but whether this restores tissue-specific NAD+ pools uniformly remains unclear — leading researchers acknowledge that age-related NAD+ variations across tissues are inconsistent, making the functional relevance of blood-level measurements genuinely uncertain^[5].

Why did trametinib and rapamycin produce additive rather than synergistic effects?#

Because they inhibit parallel branches of the same nutrient-sensing network rather than sequential steps in a single pathway. Rapamycin blocks mTORC1; trametinib blocks MEK-ERK via the Ras arm. Since these are independent downstream effectors of the insulin–IGF signaling axis, their effects stack arithmetically rather than multiplying. Gkioni et al. found no positive or negative interaction in either sex — the combination benefit was purely additive^[3].

Who should consider geroprotective supplementation now versus waiting for more data?#

Honestly, it depends on your risk tolerance. If you're over 40, metabolically healthy, and interested in longevity optimization, starting with NAD+ precursors and periodic fasting or ketone exposure carries minimal risk and some emerging evidence of benefit. Pharmaceutical geroprotectors like rapamycin should only be considered under physician supervision with regular monitoring. Cyrene and trametinib combinations are strictly preclinical — there's no responsible consumer protocol for either yet.

When will geroprotective compounds move from research to clinical practice?#

The honest timeline is 5–10 years for regulatory approval of any compound specifically indicated for aging. Rapamycin is furthest along in off-label clinical use. The TAME trial (Targeting Aging with Metformin) may establish the regulatory framework for aging as a treatable indication. Meanwhile, the nutraceutical pathway — NAD+ precursors, spermidine, exogenous ketones — is where consumers have immediate access, though with weaker evidence standards than pharmaceutical development demands.

VERDICT#

Score: 7.5/10

The geroprotective field is genuinely advancing. The trametinib-rapamycin additive data from Partridge's group is the strongest new finding here — published in Nature Aging with clean methodology and a mechanistically satisfying explanation. The 3HB mouse data (21% median lifespan extension) is exciting but needs replication. Cyrene is a fascinating discovery-stage compound with zero translational relevance today. The human NAD+ and fasting mimetic trials show subjective improvements but are industry-funded preprints with small samples. I'm cautiously optimistic about the trajectory — the field is asking better questions and designing better studies than five years ago. But we're still largely building on preclinical foundations, and the gap between mouse lifespan data and human healthspan protocols remains wide. Don't let anyone convince you otherwise.